The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
Related Articles
The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
Cancer Prevention Overview
Cancer prevention methods include avoiding things that cause cancer, having a healthy lifestyle, getting screened, and using some medicines or surgery. Learn more about ways…
Welcome! You are invited to join a webinar: [Live Webinar] – Optimising the management of HR+ HER2- metastatic breast cancer. After registering, you will receive a confirmation email about joining the webinar.
Join this webinar on Wednesday 22 January 2025, 19:00-20:00 CET, where Etienne Brain, Evandro de Azambuja, Valentina Guarneri, Cristina Saura and Hans Wildiers will discuss…
Welcome! You are invited to join a webinar: [Live Webinar] – Optimising the management of HR+ HER2- metastatic breast cancer. After registering, you will receive a confirmation email about joining the webinar.
Join this webinar on Wednesday 22 January 2025, 19:00-20:00 CET, where Etienne Brain, Evandro de Azambuja, Valentina Guarneri, Cristina Saura and Hans Wildiers will discuss…
Enasidenib Monotherapy Shows Promise for Patients With IDH2-Mutated MDS | Blood Cancers Today
Preliminary findings from a phase II trial suggest that enasidenib offers clinically meaningful responses and a manageable safety profile in MDS.
Current Issue : Oncology Times
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
H-E-B | Curbside Pickup & Grocery Delivery | HEB.com
No store does more than your H-E-B, where you’ll find savings on products you love, without compromise of convenience, quality or selection. Free Curbside!
American Cancer Society nutrition and physical activity guideline for cancer survivors
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA)
Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-mutations.…
OCE Oncology News
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
